AbCellera Biologics (ABCL) Stock Analysis

What AbCellera Biologics does

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Key metrics

ETFs linked to ABCL

Broad-market and Healthcare sector ETFs an investor holding AbCellera Biologics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ABCL fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for AbCellera Biologics?

AbCellera Biologics trades under the ticker ABCL on NASDAQ.

Which exchange is ABCL listed on?

ABCL is listed on NASDAQ.

What sector does AbCellera Biologics operate in?

AbCellera Biologics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ABCL in a portfolio?

PortView shows ABCL's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.